Objectives: To assess safety and clinical performance of a novel bioabsorbable vascular graft in pediatric patients with univentricular cardiac malformation who received surgical correction via an extracardiac cavopulmonary conduit.
Perspective
The bioabsorbable vascular graft is easy to handle. Imaging studies demonstrated anatomical (conduit diameter and wall thickness) and functional (blood flow pattern) stability of the graft in the 5 patients with no significant changes at 12 months compared with early postoperative data.
See Editorial Commentary page 1551.
The number of newborns who suffer from life-threatening complex congenital heart disease and require cardiac surgery is approximately 100,000 per year worldwide. [1] [2] [3] The use of artificial grafts, homografts, or xenografts is standard of care to repair congenital malformations. [4] [5] [6] [7] These materials, however, typically are associated with adverse events, including rejection, chronic infection, stenosis, thromboembolic events, and calcifications. [8] [9] [10] [11] [12] [13] In addition, the current available materials are unable to grow; this means that these younger patients often require repeat surgery. 14, 15 To overcome these limitations, a new generation of vascular graft has been developed that is based on a bioabsorbable polymer matrix designed to induce autologous repair by endogenous tissue restoration, a spontaneously growing, natural, healthy tissue with cells contributed only from the recipient. Immediately after the implantation, the prosthesis is functional but with time, neotissue is formed and organizes into a fully functional blood vessel while the polymer gradually is bioresorbed.
This approach is not completely new: as early as 2001 Shinoka and Breuer developed the idea that optimal filling materials with biocompatibility and growth potential may have significant advantages for pediatric patients in whom foreign material has to be implanted as part of the reconstructive procedure. 16, 17 They reported the advantages of tissue-engineered vascular autografts in models in animals and in human clinical applications by using autologous cells and biodegradable scaffolds. The key benefit from the use of such scaffolds is that they degrade in vivo, thereby avoiding the long-term presence of foreign materials because the seeded cells proliferate and differentiate to construct new tissue. More recently, they have developed the same concept for small-caliber vascular grafts. 18, 19 
METHODS
The vascular graft is a sterile, flexible, straight, highly porous conduit composed of a bioresorbable supramolecular polyester 20 and processed by electrospinning. The polyester is obtained by chain-extending poly-caprolactone with 2-ureido-4[1H]-pyrimidinone. The 2-ureido-4 [1H]-pyrimidinone motif is self-complementary by forming quadruple hydrogen bonding; this leads to a significant improvement in mechanical properties while still allowing the material to be processed. 21 Scanning electron microscopy shows that the graft structure is made up of a scaffold of fibers (Figure 1 ). The graft matrix is flexible and strong enough to support the pressure of the cardiovascular system with a porous environment that allows and stimulates cell penetration and subsequent tissue growth, without the use of stem cells, growth factors, or animal-derived products.
Standard biocompatibility tests were performed in Good Laboratory Practices-certified laboratories according to ISO-10993. Tests included cytotoxicity, genotoxicity, pyrogenicity, and several others. All tests were passed.
A prospective first in human, clinical investigation was performed in a single center, the Bakulev Center for Cardiovascular Surgery, Moscow, Russian Federation (Clinicaltrials.gov number, NCT02377674). The new vascular graft (Xeltis AG, Zurich, Switzerland) was implanted in 5 pediatric patients aged 4 to 12 years over a recruitment period of 5 months (October 2013 to February 2014).
Ethics committee approval was gained before we began the study, and all consent forms were signed by the relatives before enrollment. The new vascular graft was implanted during the second step of a modified Fontan procedure as an extracardiac total cavopulmonary connection and therefore connected the inferior vena cava with the right pulmonary artery. Surgical technique and graft implantation were performed with the same standard as for other commercially available vascular conduits (synthetic, homograft, or xenograft) (Video 1). The patients were followed with postoperative examinations at discharge and at months 1, 3, 6, 9, and 12 after implantation. Follow-up included documentation of the patients' clinical condition and of all adverse events (related or not to the new implant), information on concomitant medication, and transthoracic echocardiographic assessment.
The data were collected for each follow-up visit and monitored by an independent clinical research assistant to ensure the accuracy of the information. All serious adverse events were reviewed by an independent clinical review committee comprising 1 cardiologist and 2 cardiac surgeons.
RESULTS
The 5 patients (3 male and 2 female) were in average New York Heart Association functional class II at entry to the trial. All patients previously had received a bidirectional cavopulmonary anastomosis (Glenn shunt), 3 a coiling occlusion of aortopulmonary collaterals, and 1 had received a modified Blalock Taussig shunt. The average age was 6.2 AE 2.9 years, and the average body mass index was 14.5 AE 2.1 (kg/m 2 ). A summary of the baseline cardiac assessments is shown in Table 1 .
All patients underwent successful graft implantation as the second step of a modified Fontan procedure ( Figure 2 ). Cardiopulmonary bypass time ranged from 83 to 120 minutes. Three patients received a graft of 18 mm in diameter and 2 received a graft of 20 mm in diameter. No total cavopulmonary connection was performed with a fenestration. This new graft does not require preclotting, and no blood was observed oozing through the prosthetic 
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4D ¼ 4-dimensional MRI ¼ magnetic resonance imaging PTFE ¼ polytetrafluoroethylene material despite full heparinization during cardiopulmonary bypass. Surgeons who performed the operation described the new material as flexible, easy to handle, and easy to suture. There were no intraoperative or postoperative complications.
No graft-related adverse events were observed during the 12-month follow-up period. Two patients with persistent pleural effusions required interventional occlusion of aortopulmonary collaterals. Transthoracic echocardiography was performed at each follow-up visit (1, 6, 9, and 12 months) and demonstrated anatomical stability and optimal function of the extracardiac conduit in all patients. Magnetic resonance imaging (MRI) was performed in 4 patients (in 1 after 9 months and in 3 after 12 months) and 4-dimensional (4D) flow imaging showed that there was laminar flow without turbulence (Figure 3 ). The fifth patient was unable to complete MRI because of an allergic reaction during the sedation before the examination. 4D flow MRI allowed for a comprehensive evaluation of blood flow patterns using blood flow visualization and flexible retrospective quantification of flow parameters. The mean left ventricular ejection fraction was 53.6 AE 9.3 at 6 months and 57.6 AE 6.1 at 12 months. Echocardiography allowed us to exclude turbulence or thrombus in the graft.
Postoperative diameters and maximal velocities in the graft are summarized in Table 2 .
One patient demonstrated an abnormal qualitative assessment of ventricular function that developed at the 6-month visit and was still apparent at 12 months. Three patients received warfarin (because of prolonged immobilization), and 2 patients were treated with aspirin as long-term anticoagulation. Two cardiacrelated adverse events were reported: bundle branch block in one and sick sinus syndrome in another patient, but neither required treatment. Four patients experienced 6 other adverse events: pleural effusions in 3, pneumonia in 1, and Dressler syndrome in 1 whereas 1 patient had significantly reduced function of the systemic ventricle. None of these adverse events was considered as related to the graft.
DISCUSSION
Preclinical studies in animals (results not shown in detail here) performed with this new graft have demonstrated that the material is well tolerated, initiating a normal tissue response as soon as it is implanted (Figure 4) . 22 These studies in animals have shown promising results in the pulmonary position: 1 year after implantation, the polymer was fully fragmented but not fully resorbed. Histologic examinations showed a bioabsorption process that is still active at this time 22 Figure 4 provides an overview of the absorption process over time: it shows a gradual replacement of the prosthetic material by autologous neotissue. The implant starts to become fragmented after 6 months and the process continues until 12 months. Contrary to polytetrafluoroethylene (PTFE), there is a very clear absorption occurring, starting with fragmentation of the polymer before it is finally digested by inflammatory cells involved in the process.
Long-term studies in sheep have shown that at 2 months and beyond, the derived burst pressure of the explant (implant þ neotissue) is in all cases greater and on average more than twice as high compared with the burst pressure of a bare scaffold implant and compared with a native pulmonary artery. The same study also demonstrated that the implant material has lost its mechanical integrity at 6 months after implantation (the graft is fragmented), indicating that functionality has been taken over completely by the newly formed tissue. 22 The endogenous tissue restoration process mimics normal tissue regeneration: mild leukocyte infiltration, ingrowth of neointima (lined with endothelium), influx of myofibroblasts, and finally collagen and elastin formation. Histologic examination at 53 weeks after implantation with hematoxylin and eosin staining highlights that there are islands of prosthetic material surrounded by a meshwork of refractile fibers with various giant cells, lymphocytic activity, and the presence of collagen fibers and blood vessels ( Figure 5 ). In some areas, the graft material is encapsulated completely in connective tissue. Mechanical testing of the explanted grafts indicated that the developed new tissue has a high burst pressure that exceeds the limits required for a commercial conduit.
Since 1983, 709 operative procedures to realize a Fontan circulation have been performed at the Bakulev Center for Cardiovascular Surgery, including 476 (67%) extracardiac cavopulmonary conduits with an overall operative mortality of 5.7%. Most of the conduits (428 or 90%) were made of expanded PTFE (W. L. Gore & Associates, Inc, Flagstaff, Ariz) with diameters ranging between 14 and 24 mm.
All patients who received this new vascular graft did well at the 12-month follow-up visit. The majority of adverse events were pleural effusions, a well-known complication after a Fontan procedure. The etiology is multifactorial, but there is no prophylactic treatment or special operative strategy to avoid postoperative pleural effusions. 23, 24 Arrhythmias commonly are reported after the modified Fontan procedure, 25 and in this small series, 2 patients experienced branch bundle block and sick sinus syndrome. These events were both classified as mild events and did not require treatment, although they were not resolved at 1 year after implantation.
No graft-related adverse events were observed during the clinical observation up to 12 months after the graft implantation. One patient experienced a significant decrease in ventricular function. This event was thought to be due to hypercirculation in the collaterals and resolved after interventional occlusion of aortopulmonary collaterals. This event was reclassified as cardiac failure by the clinical review committee. Otherwise, all significant adverse events reported were resolved at the end of the study.
Echocardiography and 4D flow MRI confirmed a normal function of the conduits with absence of thrombus and blood flow turbulence. The anatomical stability of the grafts was confirmed by the assessment of conduit diameters and wall thickness. No obstruction was seen at the level of the anastomoses or within the conduit up to 12 months after implantation.
Echocardiography, however, was limited to show precise pictures of the proximal and distal portions of the conduit, and it was not possible to estimate the length of the conduit in every patient. As expected, early assessment of the conduit via the use of echocardiography was extremely difficult up to 1-month postimplant, due to postoperative mediastinal changes.
An increasing number of ''Fontan patients'' are now entering adulthood, and these patients are facing an uncertain future because this procedure remains a palliative treatment. 26 The most common reason for reoperation is stenosis of the conduit. 27, 28 The most frequently used artificial conduits for the second step of the modified Fontan procedure (total cavopulmonary connection) include PTFE and Dacron. Dabal and colleagues 29 looked at the long-term results of PTFE conduits used for the Fontan procedure. They reviewed 207 patients over 23 years and reported that a modified Fontan operation using a 16-mm or greater extracardiac conduit combined with a bidirectional Glenn shunt offers excellent long-term survival, freedom from reoperation, and good functional state. 29 Van Brakel and colleagues 30 reported recently that the incidence of conduit stenosis in Dacron grafts was extremely high after a Fontan procedure. They retrospectively examined 12 patients who received a Dacron graft and found that 66% (8 of 12) underwent reoperation because of conduit stenosis. All explanted conduits were replaced with PTFE grafts. The explanted conduits showed tissue deposits on the inner surface. 30 Conduit size is probably the most significant independent predictor of early conduit-related intervention, most likely resulting from patient outgrowth with regard to the size of the implanted conduit. 31 Restrepo and colleagues 32 used MRI to study the flow rates in the conduit after implantation. They showed that the flow rate increased proportionally to the body surface area but that the conduit diameter did not match the somatic growth of vessel; this results in a significant energy loss over time. Oversizing of a conduit is likely to be associated with longer conduit life.
The new vascular graft presented in this paper may provide an original alternative to synthetic grafts: the conduit becomes more biocompatible with time and may reduce the need for reoperation due to outgrowth of the graft. With this in mind, it may provide a better and longer solution for pediatric patients who require a Fontan procedure to treat complex congenital diseases.
CONCLUSION
This small series confirms that this new conduit is a viable alternative to allografts and synthetically manufactured conduits. Initial clinical experience suggests that this novel technology has the potential to improve cardiac and vascular procedures by reducing permanent implant related complications. Longer follow-up, however, 
